BioCryst is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. BioCryst's core development programs include BCX7353 and additional 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema; and BCX4430 (GALIDESIVIR), a broad spectrum antiviral for hemorrhagic fevers.